Breast Cancer Home > Tykerb and Breastfeeding
While no clinical studies have been conducted on Tykerb and breastfeeding, women are typically advised to avoid breastfeeding while taking the drug. It is unknown if Tykerb passes through breast milk, but if it does, serious side effects could occur in the nursing infant. If you are taking Tykerb and breastfeeding (or are thinking of breastfeeding), talk to your healthcare provider first.
It is not known if Tykerb® (lapatinib) passes through breast milk. Because of the potentially serious side effects that could occur in the nursing infant, the manufacturer of the drug recommends that women stop breastfeeding while taking it. Therefore, if you are breastfeeding or are thinking of breastfeeding while taking the drug, make sure to let your healthcare provider know.
Tykerb is always taken in combination with Xeloda® (capecitabine) or Femara® (letrozole). Tykerb, Femara, and Xeloda have not been studied in any breastfeeding women. However, as with many cancer medications, Tykerb, Xeloda, and Femara can cause serious side effects (see Tykerb Side Effects, Femara Side Effects, and Xeloda Side Effects), which could affect a nursing infant if these medications do indeed pass through breast milk.
You should talk with your healthcare provider about Tykerb and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Tykerb and breastfeeding that is right for you.